About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 5935 record(s)
Req # A-2023-001599
Adverse Drug Reactions (ADRs). Report numbers: 001070542.Organization: Health Canada
April 2024
Req # A-2023-001618
Adverse Drug Reactions (ADRs). Report numbers: 001072019.Organization: Health Canada
April 2024
Req # A-2024-000007
Adverse Drug Reactions (ADRs) for Heparin. Report numbers: 001072985.Organization: Health Canada
April 2024
Req # A-2024-000012
Adverse Drug Reactions (ADRs). Report numbers: 001067949, 001069982.Organization: Health Canada
April 2024
Req # A-2024-000017
Adverse Drug Reaction (ADR) for ACITRETIN. Report number: 1071472. ADRs for ANASTROZOLE. Report numbers: 983160, 990116. ADR for CIPROFLOX. Report number: 1032025. ADR for Clonidine. Report number: 981372. ADRs for EPLERENONE. Reports number: 1026516, 1043922. ADRs for HYDROXYCHLOROQUINE. Report numbers: 1024918, 1026702, 1037377.Organization: Health Canada
April 2024
Req # A-2024-000028
Adverse Drug Reactions (ADRs) for Rosuvastatin-40. Report numbers: 000657015, 000702528. ADRs for Rosuvastatin-10. Report numbers: 000675846, 000928844. ADRs for Rosuvastatin-5. Report numbers: 000698101, 000705573. ADRs for Rosuvastatin-20. Report numbers: 000709470, 000720165.Organization: Health Canada
April 2024
Req # A-2024-000032
Adverse Drug Reactions (ADRs) for IBUPROFEN. Report numbers: 001049833, 001051635, 001052031, 001052040, 001052619, 001050859, 001053224, 001055320, 001065019, 001065607.Organization: Health Canada
April 2024
Req # A-2024-000068
Adverse Drug Reaction (ADR) for YESCARTA. Report number: 001076510.Organization: Health Canada
April 2024
Req # 24-2403
1. Copy of the contract(s) between VIA Rail Canada and CAD Railway Industries of Quebec for the tear-down inspection of VIA Rail Head-End Power/stainless steel fleet cars at the CAD facility from 2022 to the present, including what services were to be provided by CAD, cost of the services, project timelines and disposition of the tested cars 2. the final disposition and/or dates of scrapping of each VIA Rail Head-End Power/stainless steel fleet car tested at the CAD facility 3. the final disposition and/or dates of scrapping of each VIA Rail Head-End Power/stainless steel fleet car at the National Research Council facilities in Ottawa 4. whether any major or minor car components were provided/sold to any entity other than VIA Rail or CAD and a listing thereof. 5. For requests 2,3,4, copies of all relevant email communications sent or received by VIA Rail management and staff.Organization: VIA Rail Canada Inc.
April 2024
Nothing to report this month
Organization: Canadian Museum of Nature